GSK buys full rights to make COVID, influenza vaccines from CureVac (updated)

CureVac NV

03/07/2024 07:23

(Adds details in paragraphs 2-4)
       July 3 (Reuters) - GSK  GSK.L  has bought from CureVac
 5CV.DE ,  CVAC.O  the full rights to develop and manufacture
vaccine candidates for influenza and COVID-19 that use messenger
RNA (mRNA) technology for up to 1.05 billion euros ($1.13
billion), it said on Wednesday.
    The deal is the result of restructuring a collaboration,
which began in 2020 to develop mRNA-based vaccines for
infectious diseases, into a new licensing agreement, GSK added.
    As a result of the collaboration, the two companies have
vaccine candidates for seasonal influenza and COVID-19 in phase
II clinical development and avian influenza in phase I clinical
development.
    The new deal includes CureVac getting an upfront payment of
400 million euros and up to 1.05 billion euros in milestone and
royalty payments. 
        
    
 
 ($1 = 0.9313 euros)

 (Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio
D'Souza and Janane Venkatraman)
 ((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))